Coronavirus: CoP statement on the supply of Ibuprofen

The National Institute for Health and Care Excellence (NICE), in conjunction with the Medicines and Healthcare products Regulatory Agency (MHRA), has announced a number of ‘clinical rapid evidence reviews’ to address concerns over the impact of the use of certain medicines in COVID-19 illness.  

These reviews will look at whether certain medicines may increase the severity or length of COVID-19 illness.

The NICE review includes some medicines which are able to be sold and supplied by podiatrists. The NICE statement includes a review of:

• Ibuprofen and other non-steroidal anti-inflammatory drugs used to reduce temperature and ease flu-like symptoms

In conjunction with the MHRA, NICE will facilitate a rapid review of information and then issue advice on the safety and efficacy of treatments for COVID-19.   

In the interim period, the College of Podiatry advises members to avoid initiation of treatment involving ibuprofen and to seek alternative treatments until such time as NICE issues its conclusions and recommendations. 

Dr Paul Chadwick

Clinical Director, The College of Podiatry